China News Service, Shanghai, February 24 (Sun Guogen and Chen Jing) The reporter learned on the 24th that Chinese medical experts have discovered the "accomplice" of gastric cancer drug resistance through a large sample and multi-center study of gastric cancer patients. Individualized treatment of gastric cancer patients may have combined targets. point.
It is reported that the recent international academic journal "Journal of Tumor Immunotherapy" published relevant papers by the research team of Professor Xu Jiejie from the School of Basic Medicine of Fudan University.
According to Xu Jiejie, gastric cancer is a highly heterogeneous tumor, and there are great individual differences between different patients. Therefore, only individualized and precise treatment can achieve the best results.
The expert told reporters that at present, the postoperative survival assessment of gastric cancer patients, the prediction of chemotherapy response and the choice of treatment options for patients who are not sensitive to chemotherapy are still three major problems that plague clinicians.
In recent years, the rise of immunotherapy has provided a new strategy for the treatment of gastric cancer patients, but only 20% of patients respond to this therapy.
Further analysis of the tumor microenvironment and the functional study of key molecules are urgent issues to be solved in the treatment of gastric cancer.
Studies have found that interleukin-1 receptor 1 (IL-1R1) in gastric cancer tissue plays a key "accomplice" role in inducing local immunosuppression and treatment resistance in gastric cancer.
It is understood that, in the past, IL-1R1 was considered to play a key role in chronic inflammation.
Xu Jiejie explained to reporters that the high-level expression of this "accomplice" in gastric cancer tissue participates in the "recruitment" of macrophages associated with tumor progression, inhibits immunity, and weakens the anti-tumor immune response in the gastric cancer microenvironment.
This promotes gastric cancer drug resistance.
Since the onset of chemotherapy drugs also depends on the reactivation of the body's immune cells to "sweep" the remaining cancer cells, patients with high IL-1R1 expression are also insensitive to adjuvant chemotherapy due to the lack of the "repairing" effect of the immune system. .
The research team believes that by detecting the expression level of IL-1R1 in tissue samples of gastric cancer patients, the responsiveness of patients to related immunotherapy drugs and chemotherapy drugs can be judged.
(over)